Activity of imipenem/relebactam and comparators against gram-negative pathogens from patients with bloodstream infections in the United States and Canada - SMART 2018-2019.
Diagn Microbiol Infect Dis
; 100(4): 115421, 2021 Aug.
Article
en En
| MEDLINE
| ID: mdl-34082265
Bloodstream infections (BSI) are often caused by drug-resistant pathogens, and novel antimicrobials are needed. We examined the activity of imipenem/relebactam against BSI pathogens from US and Canada: >99% of non-Morganellaceae Enterobacterales, including 100% of MDR isolates, and >94% of Pseudomonas aeruginosa were imipenem/relebactam-susceptible. Imipenem/relebactam could provide an important treatment option.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Imipenem
/
Sepsis
/
Compuestos de Azabiciclo
/
Bacterias Gramnegativas
/
Antibacterianos
Tipo de estudio:
Screening_studies
Límite:
Humans
País/Región como asunto:
America do norte
Idioma:
En
Revista:
Diagn Microbiol Infect Dis
Año:
2021
Tipo del documento:
Article
Pais de publicación:
Estados Unidos